$2.72 -0.03 (-1.09%)

Anebulo Pharmaceuticals, Inc. Common Stock (ANEB)

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare and unmet medical conditions, particularly those related to substance use disorders. The company's lead candidate aims to address acute cannabinoid overdose and other drug-related toxicity, leveraging its proprietary research and development platform.

🚫 Anebulo Pharmaceuticals, Inc. Common Stock does not pay dividends

Company News

Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior
GlobeNewswire Inc. • Researchandmarkets.Com • July 25, 2025

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Zacks Investment Research • Zacks Equity Research • October 19, 2023

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga • Lisa Levin • October 17, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Assembly Biosciences, Inc. (NASDAQ: ASMB) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and...

Wall Street Breakfast: The Week Ahead
Seeking Alpha • Wall Street Breakfast • October 31, 2021

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.